Biognosys

Cutting-edge mass spectrometry proteomics technologies are accelerating the discovery and validation of novel targets in cancer, opening up new avenues for next-generation cancer therapeutics.

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

Although there are initiatives to de-risk the drug development process, continually applying the same tools and approaches is unlikely to lead to innovative, first- or best-in-class targets and transformative progress.

timsTOF Ultra Further Advances Quantitative Spatial and Single-cell 4D-Proteomics and 4D-Lipidomics™, Immunopeptidomics, PTM and Protein-Protein Interactions Analysis - with Speed and Robustness.

The 10-year anniversary of SWATH DIA signifies a period of immense growth that is only expected to continue to evolve, influencing a wide range of fields. This article explores key milestones for SWATH DIA since its development.

This article will cover innovations in structural proteomics, a new way to identify drug targets across the proteome, a new method to dissect drug–protein interactions and the future of structure-based drug design.

For this, we need to look at the ultimate output of the genome: the proteome. After many years in the shadow of genomics, proteomics is now ready to step into the spotlight.

Bruker Corporation and Switzerland-based Biognosys AG have announced a strategic partnership in which Bruker has made a majority-ownership investment in Biognosys.

Technology Networks had the pleasure of interviewing Dr. Oliver Rinner, CEO at Biognosys, to learn more about some of the recent developments in proteomics, and discuss what the future could hold for the field.